Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax (R) for the treatment of adult patients with locally advanced pancreatic cancer concomitant ...

FDA clears 1st treatment for pancreatic cancer in 30 years, approving Optune Pax to improve survival with chemotherapy.

The FDA approved Optune Pax (Novocure), a first-in-class portable device that delivers tumor-treating fields (TTFields) to the abdomen in adult patients with locally advanced pancreatic cancer, ...

With this decision, Optune Pax becomes the first new FDA-approved treatment for locally advanced pancreatic cancer in decades. For patients and families navigating this diagnosis, the addition of a ...

The BTD for zovegalisib is supported by data from the Phase I/II ReDiscover trial.

Cancer survival rates hit historic high: Dr. Robert Donegan explains what’s saving lives ...

In this phase 3 study, researchers sought to determine whether the addition of palbociclib may overcome resistance to endocrine and HER2-directed therapies.

Please provide your email address to receive an email when new articles are posted on . Many patients with advanced cancer receive treatments focused on longevity, even if they prioritize comfort.

The phase 2b study is an open-label trial that will enroll 40 men with advanced prostate cancer who are appropriate candidates for ADT. Participants will receive an initial loading dose of teverelix ...

Patients with advanced cancer were twice as likely to report receiving life-extending care despite an expressed preference for comfort-focused care. Discordant care did not improve 24-month survival ...